Australia's most trusted
source of pharma news
Wednesday, 22 April 2026
Posted 22 April 2026 AM
US pharmaceutical consulting company IQVIA has bought 100 per cent of Sydney-based Lucid Health Consulting, bringing the Australian regulatory specialists into the IQVIA family of companies.
The deal unites Lucid's specialised expertise with IQVIA's global capabilities across pricing and market access strategy, real-world evidence, patient programs, and commercialisation planning. It lets Lucid offer an expanded range of solutions and services to its clients.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.